N-环丙基-4-甲基苯甲酰胺 | 88229-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-环丙基-4-甲基苯甲酰胺
• 英文名称: N-cyclopropyl-4-methylbenzamide
• CAS: 88229-12-3
• 化学式: C₁₁H₁₃NO
• mdl: MFCD01907045
• 分子量: 175.23
• InChiKey: BRCUSPLHYFOGLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-环丙基-4-甲基苯甲酰胺 在 噻吩-2-甲酸亚铜(I) 、 叠氮基三甲基硅烷 、 Selectfluor 作用下， 以 乙腈 为溶剂， 反应 0.17h， 以78%的产率得到N-(1,3-diazidopropyl)-4-methylbenzamide
  参考文献：
  名称：

  通过 σ- 和 π-C-C 键的氮定向叠氮化合成二胺

  摘要：

  二胺是合成农用化学品、药物和有机材料的基本组成部分，但它们的合成仍然具有挑战性，因为需要区分两种氮并且需要不同的取代模式（1,2、1,3 或 1,4） . 我们在此报告了一种新策略，该策略基于烯烃、环丙烷和环丁烷的氮定向重氮化，将 1,2、1,3 和 1,4 酰氨基叠氮化物作为正交保护的二胺。市售的噻吩-2-羧酸铜（CuTc，2 mol%）作为催化剂，在容易获得的氧化剂和叠氮化三甲基甲硅烷基的存在下，在 10 分钟内促进了 π 和 σ C-C 键的重氮化。用碳亲核试剂（富电子芳香族、丙二酸酯、有机硅、有机硼、有机锌、

  DOI：

  10.1021/jacs.1c06700
• 作为产物：
  描述：

  对甲基苯甲酸 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-环丙基-4-甲基苯甲酰胺
  参考文献：
  名称：

  Design of novel CSA analogues as potential safeners and fungicides

  摘要：

  Study of safeners has been seldom reported in literature. In this work, a series of novel acylsulfamoylbenzamide analogues was designed and synthesized with newly developed safener cyprosulfamide (CSA) as the leading compound. The activity assay against the herbicide thiencarbazone-methyl (TCM) on maize revealed that fifteen compounds showed better protective effect than CSA on the fresh weight of aerial parts, twelve compounds exhibited better activity on the dry weight of aerial parts. Remarkably, two compounds (6Ih, 7II) had protective effect on the four aspects of TCM treated maize. Further antifungal assay showed their excellent activity against Physollospora piricola. The structure-activity relationships of CSA analogues as safeners and fungicides were discussed and it might be valuable for further molecular modification of new CSA analogues. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.085

文献信息

• NOVEL COMPOUNDS AS GPR119 AGONISTS
  申请人：Mankind Pharma Ltd.

  公开号：US20170291910A1

  公开（公告）日：2017-10-12

  The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

  本发明涉及式(I)的新化合物作为GPR119激动剂，包含此类化合物的组合物及其制备方法。
• DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE
  申请人：BRAUN Alain

  公开号：US20090176775A1

  公开（公告）日：2009-07-09

  The present invention is related to a compound of formula (I): wherein i, j, n, o, p, q, r, R 1a , R 1b , R 1c , R 1d , R 2a , R 2b , R 2c , R 2d , R 3a , R 3b and R 4 are as defined herein, or an addition salt with an acid thereof, or a hydrate or solvate thereof, its preparation, pharmaceutical composition, and uses for treating a disease in which the enzyme 11β-HSD1 is involved.

  本发明涉及一种具有以下式（I）的化合物： 其中i、j、n、o、p、q、r、R1a、R1b、R1c、R1d、R2a、R2b、R2c、R2d、R3a、R3b和R4如本文所定义，或其与酸的加合盐，或其水合物或溶剂合物，其制备、药物组合物以及用于治疗11β-HSD1酶参与的疾病的用途。
• Fluoro substituted 2-oxo-azepan derivatives
  申请人：Flohr Alexander

  公开号：US20070037789A1

  公开（公告）日：2007-02-15

  The invention relates to compounds of general formula wherein R 1 , R 2 , R 3 /R 3′ , R 4 /R 4′ and R 5 /R 5′ are as defined in the specification and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are γ-secretase inhibitors which can be useful in the treatment of Alzheimer's disease or common cancers including, but not limited to, cervical carcinomas and breast carcinomas and malignancies of the hematopoietic system.

  本发明涉及具有通式化合物，其中R1，R2，R3/R3′，R4/R4′和R5/R5′按说明书定义，以及药用可接受的酸加成盐，光学纯对映体，外消旋混合物或对映体混合物。所述化合物为γ-分泌酶抑制剂，可用于治疗阿尔茨海默病或常见癌症，包括但不限于宫颈癌，乳腺癌和造血系统的恶性肿瘤。
• Phthalazine, aza- and diaza-phthalazine compounds and methods of use
  申请人：Tasker Andrew

  公开号：US20060199817A1

  公开（公告）日：2006-09-07

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , B, R 1 , R 2 , R 3 and R 4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

  本发明包括一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症及相关状况。这些化合物的通用公式为I 其中A 1 ，A 2 ，B，R 1 ，R 2 ，R 3 和R 4 在此定义。该发明还包括包括一个或多个I公式化合物的药物组合物，以及使用这些化合物和组合物治疗激酶介导的疾病，包括类风湿性关节炎，银屑病和其他炎症性疾病，以及用于制备I公式化合物的中间体和工艺。
• [EN] 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA KINASE P38 A BASE D'HETEROCYCLES A 5 CHAINONS
  申请人：TRIAD THERAPEUCTICS INC

  公开号：WO2005009973A1

  公开（公告）日：2005-02-03

  Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including method of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders, including, but not limited to, inflammatory diseases and disorders.

  提供了基于5-成员杂环的p38激酶抑制剂。进一步提供了基于吡唑和咪唑的p38激酶抑制剂，包括p38α和p38β激酶。还提供了含有这些化合物的药物组合物。还提供了这些化合物和组合物的使用方法，包括治疗、预防或改善p38激酶介导的疾病和疾病的一个或多个症状的方法，包括但不限于炎症性疾病和疾病。